A millimeter-wave inflatable frequency-agile elastomeric antenna

This letter reports a millimeter-wave frequency agile microstrip antenna printed on an ultrasoft elastomeric PDMS substrate. The microstrip patch antenna is supported by a PDMS membrane suspended over an air cavity. The distance H between the patch and the ground plane, and thus the resonant frequency of the antenna, are tuned using pneumatic actuation, taking advantage of the extreme softness of the PDMS membrane. A continuous frequency shift varying from 55.35 to 51 GHz ( ≈8%) has been obtained for a tuning range of H between 200µm and 575µm. In all configurations, the antenna remains matched and its radiation characteristics are very satisfactory

A millimeter-wave microstrip antenna array on ultra-flexible micromachined polydimethylsiloxane (PDMS) polymer

The use of Polydimethylsiloxane (PDMS), an ultra flexible polymer, as a substrate for the realization of reconfigurable microwave devices in the 60-GHz band is presented. As bulk PDMS is demonstrated to be lossy at millimeter waves, membrane-supported devices are considered. A new reliable and robust technological process has been developped to micromachine membrane-supported transmission lines and microstrip antenna arrays. It is shown that transmission lines printed on 20-µm thick membranes exhibit similar performances as bulk substrates commonly used at millimeter-wave frequencies. A microstrip antenna array has been also designed and fabricated to demonstrate the feasibility of directive antennas supported by large membranes. Promising applications for mechanical beam-steering, beam forming and frequency tunable antennas are expected

The equilibrium distribution of magnetization and the processes of magnetization reversal in magnetoelastic nanostructures

International audienc

DOMAIN WALLS IN MAGNETO-ELASTIC HETEROSTRUCTURES:MODELING AND EXPERIMENT

International audienc

Elaboration of a Novel Design Pirani Pressure Sensor for High Dynamic Range Operation and Fast Response Time

AbstractWe report a novel design for realizing Pirani sensor with a working range from a 1kPa up to pressure over than atmospheric one. The sensor is specifically designed to achieve high sensitivity, fast response time and high robustness. The proof of concept is composed of four metallic resistors interconnected to form a Wheatstone bridge. Two of them act simultaneously as the heating and sensing elements and the two others are used as a temperature reference. The heating element consists of a metallic wire of platinum Pt (3μm width, 1mm length) maintained on each lateral side by periodic silicon oxide SiO2 micro-bridges. The sensor design, fabrication technologies, electrical characterizations and voltage-pressure responses are described and shown. A future perspective is given, which describe the extension of this concept to elastic wave transduction of pressure using a combination of heater element and thin plate elastic waveguide

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with >80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Methods Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. Results A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). Conclusions Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.